Cited by 111Drug-Induced Hepatotoxicity and ProtectionLiver Disease Diagnosis and TreatmentPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure

Murphy, Elizabeth J., Davern, Timothy J., Shakil, A. Obaid, Shick, Lawton, Masharani, Umesh, Chow, Hsichao, Freise, Chris, Lee, William M., Bass, Nathan M.·2000·Digestive Diseases and Sciences

DOI 10.1023/a:1005405526283

Open this paper in CoChat — free account

Abstract

The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury. Thus, troglitazone should be prescribed with caution and should not be used as a first-line agent in the treatment of type II DM when potentially less toxic alternatives are available. It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone. Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity. If troglitazone is used, frequent monitoring of serum aminotransferases and symptoms is mandatory. However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable. Thus, the value of close monitoring and when, if ever, it is safe to stop such monitoring are currently unclear.

Integrity signals

Registry

Crossref · 10.1023/a:1005405526283

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B. H., Beerdsen, P., Joyce, M., & Olefsky, J. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 913
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 443
Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus
Schwartz, S. L., Raskin, P., Fonseca, V. A., & Graveline, J. F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381302 · Cited by 327
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 229
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Drug-induced liver disease
Zimmerman, H. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70097-0 · Cited by 186
An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis
Shibuya, A., Watanabe, M., Fujita, Y., Saigenji, K., Kuwao, S., Takahashi, H., & Takeuchi, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2140 · Cited by 104
Fatal Hepatotoxicity Associated with Troglitazone
Vella, A. V., de Groen, P. C., & Dinneen, S. F. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00032 · Cited by 76
10.1016/b978-0-323-44355-5.00011-3
(2000) · Time to knit · doi:10.1016/b978-0-323-44355-5.00011-3 · Cited by 1

Show all 10 references

Research works printed but not linked: 2

Farrell GC: Liver disease caused by drugs, anesthetics, and toxins. In Gastrointestinal Disease. M Feldman, BF Scharschmidt, MH Sleisenger (eds). Philadelphia, WB Saunders, 1998, pp 1221-1252
Parke-Davis: Prescribing information for Rezulin. Parke-Davis, Morris Plains, New Jersey, July 1998

Sorted by citations

Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Self-citation
Drug-induced hepatotoxicity
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Self-citation
Oral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,063
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy‐Wenzig, E., Blunder, M., Liu, X., Malainer, C., Blažević, T., Schwaiger, S., Rollinger, J. M., Heiß, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 616
Chemistry and Biochemistry of Type 2 Diabetes
Ross, S. A., Gulve, E. A., & Wang, M. (2004) · Chemical Reviews · doi:10.1021/cr0204653 · Cited by 326
Drug–Induced Liver Injury: Mechanisms and Test Systems
Bissell, M. D., Gores, G. J., Laskin, D. L., & Hoofnagle, J. H. (2001) · Hepatology · doi:10.1053/jhep.2001.23505 · Cited by 265
Idiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 264
Drug-Induced Liver Disorders
Kaplowitz, N. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00001 · Cited by 261
Drug-induced liver disease
Chitturi, S., & Farrell, G. C. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0034-7 · Cited by 221
Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose
Obach, R. S., Kalgutkar, A. S. S., Soglia, J. R., & Zhao, S. X. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800161s · Cited by 215
Troglitazone-induced liver failure: a case study
Graham, D. J., Green, L., Senior, J. R., & Nourjah, P. A. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01529-2 · Cited by 188
Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions
Lee, W. M., & Senior, J. R. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522356 · Cited by 187
Self-citation
A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity
Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00051-0 · Cited by 181
Diabetes increases the risk of acute hepatic failure
El‐Serag, H. B., & Everhart, J. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.33650 · Cited by 175
A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus
Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., Takahashi, T., Miyoshi, K., Nakamura, K., Izumi, T., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00014-6 · Cited by 174
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Thiazolidinediones and liver toxicity.
Scheen, A. J. (2001) · PubMed · Cited by 156
Hepatotoxicity with Thiazolidinediones
Scheen, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00002 · Cited by 142
Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models
Deng, X., Luyendyk, J. P., Ganey, P. E., & Roth, R. A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001727 · Cited by 139
Important Elements for the Diagnosis of Drug-Induced Liver Injury
Agarwal, V. K., McHutchison, J. G., & Hoofnagle, J. H. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.02.008 · Cited by 138
Inflammation and Drug Idiosyncrasy—Is There a Connection?
Roth, R. A., Luyendyk, J. P., Maddox, J. F., & Ganey, P. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041624 · Cited by 137
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham, D. J. (2001) · JAMA · doi:10.1001/jama.286.7.831 · Cited by 136
Troglitazone and liver injury
Chojkier, M. (2005) · Hepatology · doi:10.1002/hep.20567 · Cited by 129
Idiosyncratic Drug-Induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 117
Hepatotoxicity of the thiazolidinediones
Tolman, K. G., & Chandramouli, J. C. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00020-5 · Cited by 115
Idiosyncratic Toxicity: A Convergence of Risk Factors
Ulrich, R. G. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.072905.160823 · Cited by 111
Hepatotoxicity of thiazolidinediones
Isley, W. L. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.6.581 · Cited by 110
The obesity epidemic and its cardiovascular consequences
Behn, A., & Ur, E. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231406.84554.96 · Cited by 104
Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides
Fukunaga, Y., Itoh, H., Doi, K., Tanaka, T., Yamashita, J. K., Chun, T., Inoue, M., Masatsugu, K., Sawada, N., Saito, T., et al. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00430-0 · Cited by 101
Drug-Induced Liver Disease
Kaplowitz, N. (2002) · CRC Press eBooks · doi:10.1201/b15279 · Cited by 100
The prince and the pauper. A tale of anticancer targeted agents
Dueñas‐González, A., García‐López, P., Herrera, L. A., Medina‐Franco, J. L., González‐Fierro, A., & Candelaria, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-82 · Cited by 94
Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
Arnouts, P., Bolignano, D., Nistor, I., Bilo, H. J. G., Gnudi, L., Heaf, J. G., & Biesen, W. V. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft462 · Cited by 89
Cell death in drug-induced liver injury
Iorga, A., & Dara, L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.01.006 · Cited by 88
Drug‐induced hepatotoxicity
LEE, W. M. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00123.x · Cited by 86
Self-citation
Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone
Graham, D. J., Drinkard, C. R., & Shatin, D. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05843-4 · Cited by 80
Animal models of idiosyncratic drug-induced liver injury—Current status
Roth, R. A., & Ganey, P. E. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.575765 · Cited by 79
A Cohort Study of the Incidence of Serious Acute Liver Injury in Diabetic Patients Treated With Hypoglycemic Agents
Chan, K. A., Truman, A. F., Gurwitz, J. H., Hurley, J. S., Martinson, B. C., Platt, R. G., Everhart, J. E., Moseley, R. H., Terrault, N. A., Ackerson, L., et al. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.728 · Cited by 75
The stepwise approach to the management of type 2 diabetes
Warren, R. E. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.002 · Cited by 70
Mechanisms and Outcomes of Drug- and Toxicant-Induced Liver Toxicity in Diabetes
Wang, T., Shankar, K., Ronis, M. J. J., & Mehendale, H. M. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215100 · Cited by 68
Drug‐Induced Liver Injury
Pessayre, D., & Larrey, D. G. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch14a · Cited by 54
Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis
RAJAGOPALAN, R., Rosenson, R. S., FERNANDES, A., Khan, M. A., & MURRAY, F. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.016 · Cited by 48
Assessing causality in drug-induced liver injury
Lee, W. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80136-1 · Cited by 48
Self-citation
Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials
Du, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47
Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?
Roth, R. A., Maiuri, A. R., & Ganey, P. E. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237578 · Cited by 39
Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus
Strowig, S. M., & Raskin, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00440.x · Cited by 38
Drug therapy of diabetes in the elderly
Oiknine, R., & Mooradian, A. D. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(03)00052-0 · Cited by 37
Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
Brinker, A. D., Lyndly, J., Tonning, J. M., Moeny, D. G., Levine, J. G., & Avigan, M. (2013) · Drug Safety · doi:10.1007/s40264-013-0116-9 · Cited by 36
Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats
Li, J., Kaneko, T., Wang, Y., Qin, L., Wang, P., & Sato, A. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00143-9 · Cited by 36
Hepatic injury due to drugs, herbal compounds, chemicals and toxins
Lewis, J. H., & Kleiner, D. E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00013-1 · Cited by 34
Clinical Manifestations and Treatment Options in Patients with Cirrhosis and Diabetes Mellitus
Gundling, F., Seidl, H., Strassen, I., Haller, B., Siegmund, T., Umgelter, A., Pehl, C., Schepp, W., & Schumm‐Draeger, P. ‐. (2013) · Digestion · doi:10.1159/000343458 · Cited by 33
Oral antidiabetic agents as cardiovascular drugs
Macfarlane, D. P., Paterson, K., & Fisher, M. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00592.x · Cited by 31
Insulin Sensitizers
Zangeneh, F., Kudva, Y. C., & Basu, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.471 · Cited by 31
Effect of dabai (Canarium odontophyllum) fruit extract on biochemical parameters of induced obese–diabetic rats
Mokiran, N. N., Ismail, A., Azlan, A., Hamid, M., & Hassan, F. A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.03.007 · Cited by 26
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile
Obermoser, V., Urban, M. E., Murgueitio, M. S., Wolber, G., Kintscher, U., & Gust, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.027 · Cited by 26
Gene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity Screening
Vansant, G., Pezzoli, P., Saiz, R., Birch, A., Duffy, C., Ferre, F., & Monforte, J. (2006) · International Journal of Toxicology · doi:10.1080/10915810600605690 · Cited by 25
Drug-induced liver disease
Marino, G., & Lewis, J. H. (2001) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200105000-00006 · Cited by 25
Drugs and Toxins
Kleiner, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00012-1 · Cited by 24
Hepatotoxicity of thiazolidinediones
Isley, W. L., & Oki, J. C. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00159.x · Cited by 24
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone
Rajagopalan, R., Iyer, S. S., & Pérez, A. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00382.x · Cited by 22
Polycystic Ovary Syndrome Hyperandrogenism, and Insulin Resistance
Zacur, H. A. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70183-2 · Cited by 21
Production of a reactive metabolite of troglitazone by electrochemical oxidation performed in nonaqueous medium
Tahara, K., Nishikawa, T., Hattori, Y., Iijima, S., Kouno, Y., & Abe, Y. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2009.06.002 · Cited by 20
A liquid chromatography/tandem mass spectrometry method for detecting UGT‐mediated bioactivation of drugs as their N ‐acetylcysteine adducts in human liver microsomes
Harada, H., Endo, T., Momose, Y., & Kusama, H. (2009) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3912 · Cited by 17
Synthetic Thiazolidinediones: Potential Antidiabetic Compounds
Ortíz, A., & Sansinenea, E. (2010) · Current Organic Chemistry · doi:10.2174/138527211793797774 · Cited by 17
The starch from Solanum lycocarpum St. Hill. fruit is not a hypoglycemic agent
de Oliveira, A. C. P., Endringer, D. C., Araújo, R. J. P., Brandão, M. G. L., & Coelho, M. M. (2003) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2003000400017 · Cited by 16
Thiazolidinediones in Patients with Diabetes Mellitus and Heart Failure
Macfarlane, D. P., & Fisher, M. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606050-00002 · Cited by 14
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes
Jawa, A., & Fonseca, V. A. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.001 · Cited by 14
Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system
Deng, Q., Yang, Y., Liu, Y., Zou, M., Huang, G., SHI-QI, Y., Li, L., Qu, Y., Luo, Y., & Zhang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1335836 · Cited by 13
Clinical applications of drug desensitization in the Asia-Pacific region
Thong, B. Y. (2011) · Asia Pacific Allergy · doi:10.5415/apallergy.2011.1.1.2 · Cited by 13
Acute liver failure
Fontana, R. J., & Quallich, L. G. (2001) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200105000-00013 · Cited by 13
Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management
Lingvay, I., Rhee, C., & Raskin, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_10 · Cited by 12
Influence of the structures of α-halo ketones and thioamides on the Hantzsch synthesis of thiazoles and thiazolo[5,4-b]indoles. A new approach to 4-acetyl-2-methyl-4H-thiazolo[5,4-b]indole
Lepioshkin, A., Turchin, K. F., Седов, А. Л., & VELEZHEVA, V. S. (2007) · Russian Chemical Bulletin · doi:10.1007/s11172-007-0219-5 · Cited by 12
Anti-diabetic Effects of Fermented Green Tea in KK-AyDiabetic Mice
Lee, S., Park, S.-L., Nam, Y., Yi, S.-H., & Lim, S. (2013) · Korean Journal of Food Science and Technology · doi:10.9721/kjfst.2013.45.4.488 · Cited by 11
Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer
Standing, D., Dandawate, P. R., Gunewardena, S., Covarrubias‐Zambrano, O., Roby, K. F., Khabele, D., Jewell, A., Tawfik, O. W., Bossmann, S. H., Godwin, A. K., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06717-3 · Cited by 10
Leukotriene antagonists
Davern, T. J., & Bass, N. M. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00031-x · Cited by 10
Self-citation
Acute Liver Failure
Larson, A. M. (2008) · Disease-a-Month · doi:10.1016/j.disamonth.2008.03.008 · Cited by 10
Developing an optimal approach to global drug safety
Balkrishnan, R., & Furberg, C. D. (2001) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2001.00883.x · Cited by 10
Mechanistic Understanding of Idiosyncratic Drug-Induced Hepatotoxicity Using Co-Cultures of Hepatocytes and Macrophages
Villanueva-Bádenas, E., Donato, M. T., & Tolosa, L. (2023) · Antioxidants · doi:10.3390/antiox12071315 · Cited by 9
Engineering-inspired approaches to study β-cell function and diabetes
Lewis, P. L., & Wells, J. M. (2021) · Stem Cells · doi:10.1002/stem.3340 · Cited by 8
Toxic and Drug-Induced Disorders of the Liver
Bioulac‐Sage, P., & Balabaud, C. P. (2009) · Elsevier eBooks · doi:10.1016/b978-141604059-0.50043-6 · Cited by 7
Role of the Adaptive Immune System in Idiosyncratic Drug-Induced Liver Injury
Uetrecht, J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00011-x · Cited by 6
Characterization of Telmisartan‐Derived PPARγ Agonists: Importance of Moiety Shift from Position 6 to 5 on Potency, Efficacy and Cofactor Recruitment
Herbst, L., Goebel, M., Bandholtz, S., Gust, R., & Kintscher, U. (2012) · ChemMedChem · doi:10.1002/cmdc.201200337 · Cited by 6
Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer‐bearing dogs
Frazier, S. A., McKemie, D. S., Guerrero, T. A., LaChapelle, H. M., Skorupski, K. A., Kass, P. H., & Rodriguez, C. O. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00322.x · Cited by 6
[Effect of omega-3 fatty acids on the lipid structure of HIV-positive patients on antiretroviral therapy: personal observation of 20 subjects].
Ranieri, R. (2007) · PubMed · Cited by 5
Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins
Kleiner, D. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00012-0 · Cited by 4
Features and Mechanisms of Drug‐Induced Liver Injury
Pessayre, D., Berson, A., & Fromenty, B. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch5 · Cited by 4
Efficacy of liver transplantation for acute hepatic failure: a single-center experience
Shi, X., Xu, H., Ji, W., Liang, Y., Duan, W.-D., He, L., Wang, M., & Zhao, Z. (2011) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(11)60062-3 · Cited by 4
Hepatic Toxicology
Jones, A. L., & Dargan, P. I. (2007) · Elsevier eBooks · doi:10.1016/b978-0-7216-0693-4.50016-5 · Cited by 3
Pathology of the liver
Lefkowitch, J. H. (2001) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200105000-00002 · Cited by 3
Drug- and Toxin-Induced Liver Cell Injury
Kanel, G. C., & Korula, J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0765-6.10005-9 · Cited by 2
Drug-Induced Liver Disease
(2007) · CRC Press eBooks · doi:10.3109/9781420021141-2 · Cited by 2
Diabetes und Leberzirrhose
Gundling, F., & Schepp, W. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1067-6 · Cited by 2
Current Antidiabetic Therapies and Mechanisms
Wang, M. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch10 · Cited by 1
Acute Liver Failure
Larson, A. M. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch19 · Cited by 1
Drug and Toxin-Induced Liver Injury
Kanel, G. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-82533-7.00006-5 · Cited by 1
Diabetic Control Agents
Burns, M. J., & Levine, M. (2007) · Elsevier eBooks · doi:10.1016/b978-0-7216-0693-4.50069-4 · Cited by 1
Der hepatogene Diabetes bei Leberzirrhose
Gundling, F., Schepp, W., & Schumm-Draeger, P. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Drug Development for Metabolic Diseases: Past, Present and Future
Wang, M. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch18
In vitro characterization of telmisartan-derived compounds for selective peroxisome-proliferator activated receptor gamma (PPARγ) modulation
Herbst, L. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-11667

Authors: Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M.
Affiliations: University of Pittsburgh (US)
ORCID: Murphy, Elizabeth J.
Masharani, Umesh
Freise, Chris
Lee, William M.
Venue: Digestive Diseases and Sciences
Publisher: Springer Science and Business Media LLC
Published: 2000-03
Volume: 45
Issue: 3
Pages: 549-553
ISSN: 0163-2116 (ISSN-L)
1573-2568
DOI: 10.1023/a:1005405526283
OpenAlex: W2288490027
Cited by: 111
References: 10
Citations by year: 2026: 1 · 2024: 3 · 2023: 4 · 2021: 1 · 2019: 1 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 8 · 2012: 7
FWCI: 9.44
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Digestive Diseases and Sciences (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Diabetes and Digestive and Kidney Diseases (R03 DK5287-01)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: troglitazone, acute liver failure, drug-induced liver injury, hepatotoxicity, thiazolidinediones, type 2 diabetes, idiosyncratic hepatotoxicity, adverse drug reactions
MeSH terms: Troglitazone, Chromans, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Liver, Middle Aged, Thiazoles, Liver Failure, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks